Using genomic testing to access the suitability of breast cancer patients for chemotherapy - European Medical Journal

Using genomic testing to access the suitability of breast cancer patients for chemotherapy

Oncology

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph Gligorov, MD, PhD, of Sorbonne Université, Paris, France, discusses the use of genomic tests as predictive tools for adjuvant chemotherapy benefit in the management of patients with breast cancer.

This content is supported by Genomic Health, Inc.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now